Travis B Nielsen

List of Publications by Year
in descending order

24	1,511	623574	610775
papers	citations	14 h-index	24 g-index

25	25	25	2419
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clinical Microbiology Reviews, 2017, 30, 409-447.	5.7	773
2	SERPINB1-mediated checkpoint of inflammatory caspase activation. Nature Immunology, 2019, 20, 276-287.	7.0	87
3	Host Fate is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia. Journal of Infectious Diseases, 2015, 211, 1296-305.	1.9	79
4	Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis. Journal of Infectious Diseases, 2017, 216, 489-501.	1.9	67
5	Sustainable Discovery and Development of Antibiotics â€" Is a Nonprofit Approach the Future?. New England Journal of Medicine, 2019, 381, 503-505.	13.9	61
6	Capsule carbohydrate structure determines virulence in Acinetobacter baumannii. PLoS Pathogens, 2021, 17, e1009291.	2.1	59
7	Ly6G-mediated depletion of neutrophils is dependent on macrophages. Results in Immunology, 2016, 6, 5-7.	2.2	54
8	Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. MBio, 2017, 8, .	1.8	52
9	A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii. Nature Microbiology, 2020, 5, 1134-1143.	5.9	50
10	Transferrin Iron Starvation Therapy for Lethal Bacterial and Fungal Infections. Journal of Infectious Diseases, 2014, 210, 254-264.	1.9	42
11	Antibodies, Immunity, and COVID-19. JAMA Internal Medicine, 2021, 181, 460.	2.6	34
12	Natural history of Acinetobacter baumannii infection in mice. PLoS ONE, 2019, 14, e0219824.	1.1	26
13	Selectable Markers for Use in Genetic Manipulation of Extensively Drug-Resistant (XDR) Acinetobacter baumannii HUMC1. MSphere, 2017, 2, .	1.3	17
14	Monoclonal Antibody Therapy against Acinetobacter baumannii. Infection and Immunity, 2021, 89, e0016221.	1.0	17
15	Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studies. BMC Microbiology, 2015, 15, 252.	1.3	15
16	Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia. Journal of Visualized Experiments, 2018, , .	0.2	15
17	Vaccines targeting Staphylococcus aureus skin and bloodstream infections require different composition. PLoS ONE, 2019, 14, e0217439.	1.1	13
18	Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2019, 74, 2631-2639.	1.3	12

#	Article	IF	Citations
19	Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection. Journal of Infectious Diseases, 2021, 224, 2133-2147.	1.9	12
20	Evaluation of serotypes 5 and 8 capsular polysaccharides in protection againstStaphylococcus aureusin murine models of infection. Human Vaccines and Immunotherapeutics, 2017, 13, 1609-1614.	1.4	10
21	Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board. Annals of Internal Medicine, 2019, 171, 580.	2.0	7
22	Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	5
23	Introducing antimicrobial stewardship to the outpatient clinics of a suburban academic health system. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	1
24	971. The Role of Inflammation and Innate Effectors in Passive Immunization for Acinetobacter baumannii Infections. Open Forum Infectious Diseases, 2019, 6, S33-S33.	0.4	0